HPGDS and neoplasm: Brostallicin has shown very promising activity in experimental tumour models; its in vitro and in vivo activity is increased in tumour cells with higher glutathione (GSH) and/or glutathione-S-transferase (GST) levels (Geroni et al, 2002).